Mobilization of Peripheral Blood Progenitor Cells by Betafectin® PGG‐Glucan Alone and in Combination with Granulocyte Colony‐Stimulating Factor
Open Access
- 1 May 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 16 (3) , 208-217
- https://doi.org/10.1002/stem.160208
Abstract
Betafectin® PGG-Glucan, a novel β-(1,6) branched β-(1,3) glucan purified from the cell walls of Saccharomyces cerevisiae, has been shown to synergize with myeloid growth factors in vitro and to enhance hematopoietic recovery in myelosuppressed mice and primates. Here we report that PGG-Glucan is also capable of mobilizing peripheral blood progenitor cells (PBPC). PGG-Glucan (0.5 mg/kg to 16 mg/kg) was administered intravenously to C3H/HeN male mice and blood collected at times ranging from 30 min to seven days after injection. Based on granulocyte-macrophage colony-forming cell (GM-CFC) levels, peak mobilization occurred 30 min after a 2 mg/kg PGG-Glucan dose. At this time GM-CFC numbers in PGG-Glucan-treated mice were approximately fourfold greater than in saline-treated control mice. A second, smaller wave of GM-CFC mobilization (approximately twofold increase) also occurred on days 4 and 5 after PGG-Glucan treatment. Mobilization was not associated with the induction of α-chemokines, which have recently been reported to induce rapid progenitor cell mobilization. Competitive repopulation experiments performed in irradiated female C3H/HeN mice revealed that, at three months after transplantation, more male DNA was present in bone marrow, splenic, and thymic tissues from animals transplanted with cells obtained from mice 30 min after a 2 mg/kg PGG-Glucan dose than in tissues from animals transplanted with cells obtained from saline-treated mice. Additional experiments evaluated the mobilization effects of PGG-Glucan (2 mg/kg) administered to mice which had been pretreated for three consecutive days with G-CSF (125 μg/kg/day). When blood was collected 30 min after PGG-Glucan treatment, the number of GM-CFC mobilized in combination-treated mice was additive between the number mobilized in mice treated with G-CSF alone and the number mobilized in mice treated with PGG-Glucan alone. These studies demonstrate that: A) PGG-Glucan can rapidly mobilize PBPC; B) the kinetic pattern of PGG-Glucan-induced mobilization is different from that of the CSFs; C) the reconstitutional potential of PGG-Glucan mobilized cells is greater than that of steady-state PBPC, and D) PGG-Glucan can enhance G-CSF-mediated PBPC mobilization.Keywords
This publication has 39 references indexed in Scilit:
- Homing and Trafficking of Hemopoietic Progenitor CellsActa Haematologica, 1997
- Glucan-Based Macrophage StimulatorsClinical Immunotherapeutics, 1996
- Optimization of Peripheral Blood Stem Cell MobilizationThe International Journal of Cell Cloning, 1996
- Do autologous peripheral blood cell transplants provide more than hematopoietic recovery?The International Journal of Cell Cloning, 1995
- Comparative effects of particulate and soluble glucan on macrophages of C3H/HeN and C3H/HeJ miceInternational Journal of Immunopharmacology, 1992
- Dynamics of Blood Components and Peritoneal Fluid during Treatment of Murine E. coli Sepsis with beta-1,3-D-polyglucose Derivatives.Scandinavian Journal of Immunology, 1990
- Enhancement of interleukin-1 and interleukin-2 production by soluble glucanInternational Journal of Immunopharmacology, 1987
- A comparative evaluation of particulate and soluble glucan in an endotoxin modelInternational Journal of Immunopharmacology, 1986
- Stimulated hemopoiesis and enhanced survival following glucan treatment in sublethally and lethally irradiated miceInternational Journal of Immunopharmacology, 1985
- Temporal Response of Murine Pluripotent Stem Cells and Myeloid and Erythroid Progenitor Cells to Low-Dose Glucan TreatmentActa Haematologica, 1983